Peregrine Announces Date of 2017 Annual Meeting of Stockholders
November 13 2017 - 8:05AM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP) today
announced that its 2017 Annual Meeting of Stockholders will be held
on January 18, 2018, at 14191 Myford Road, Tustin, California
92780, located within the company’s manufacturing campus. Holders
of the company’s common stock at the close of business on November
27, 2017, the record date, will be entitled to receive notice of
and vote their shares at the 2017 Annual Meeting.
About Peregrine Pharmaceuticals, Inc.Peregrine
Pharmaceuticals, Inc. is a company transitioning from an R&D
focused business to a pure play contract development and
manufacturing organization (CDMO). Peregrine's in-house CDMO
services, including cGMP manufacturing and development
capabilities, are provided through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com).
The company is pursuing to license or sell its proprietary
R&D assets, including its lead immunotherapy candidate,
bavituximab, which is currently being evaluated in clinical trials
in combination with immune stimulating therapies for the treatment
of various cancers. For more information, please visit
www.peregrineinc.com.
About Avid Bioservices, Inc.Avid Bioservices,
Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals,
provides a comprehensive range of process development, high quality
cGMP clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 20 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, Avid's services
include cGMP clinical and commercial product manufacturing,
purification, bulk packaging, stability testing and regulatory
strategy, submission and support. The company also provides a
variety of process development activities, including cell line
development and optimization, cell culture and feed optimization,
analytical methods development and product characterization. For
more information about Avid, please visit www.avidbio.com.
Important Additional Information Peregrine
intends to file a proxy statement with the Securities and Exchange
Commission (SEC) in connection with the solicitation of proxies for
Peregrine's 2017 Annual Meeting (Proxy Statement) with an
associated WHITE proxy card. Peregrine, its directors and certain
of its executive officers will be participants in the solicitation
of proxies from stockholders in respect of the 2017 Annual Meeting.
Information regarding the names of Peregrine's directors and
executive officers and their respective interests in Peregrine by
security holdings or otherwise is set forth in the Annual Report on
Form 10-K of Peregrine, for the fiscal year ended April 30, 2017,
filed with the SEC on July 14, 2017, as amended by Amendment No. 1
on Form 10-K/A filed with the SEC on August 28, 2017, and
Peregrine's proxy statement for the 2016 Annual Meeting, filed with
the SEC on August 26, 2016. To the extent holdings of such
participants in Peregrine's securities are not reported, or have
changed since the amounts described, in the Form 10-K/A, such
changes have been reflected on Initial Statements of Beneficial
Ownership on Form 3 or Statements of Change in Ownership on Form 4
filed with the SEC. Details concerning the nominees of Peregrine's
Board of Directors for election at the 2017 Annual Meeting will be
included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION,
INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL
RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING
THE COMPANY'S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS
THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors
and stockholders will be able to obtain a copy of the definitive
proxy statement and other documents filed by Peregrine free of
charge from the SEC's website, www.sec.gov. Peregrine's
stockholders will also be able to obtain, without charge, a copy of
the definitive Proxy Statement and other relevant filed documents
by directing a request by mail to Peregrine, Corporate Secretary's
Office, 14282 Franklin Avenue, Tustin, CA 92780, by calling
Peregrine's proxy solicitor, MacKenzie Partners, Inc., toll-free at
(800) 322-2885, or from Peregrine's website at
www.Peregrine.com.
Media ContactsJohn Christiansen / Matt ReidSard
Verbinnen & Co(415) 618-8750 / (310) 201-2040
Investor ContactsStephanie Diaz Vida Strategic
Partners(415) 675-7401
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024